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Reigniting the TORCH: Chronic Obstructive Pulmonary Disease
Mortality and Inhaled Corticosteroids Revisited
In 2007, the TORCH (Toward a Revolution in Chronic Obstructive
Pulmonary Disease [COPD] Health) investigators, including myself,
published the results of the first multinational randomized controlled
trial to examine whether receiving an inhaled corticosteroid (ICS)
and a long-acting b-agonist (LABA) could reduce the risk of dying
compared with then-routine inhaled short-acting bronchodilator
treatment (1). TORCH did not meet its prespecified level of statistical
significance, with a famously marginal P value for treatment difference
of 0.052. Subsequent editorials, textbooks, and treatment guidelines
affirmed that inhaled drug therapy in general and regimes including ICS
specifically did not modify the risk of death in patients with COPD.
This situation is surprising, as there are ample data showing that these
treatments reduce the risk of COPD exacerbations (2), a known risk
factor for death (3), and a more recent systematic review found that
inhaled treatment reduced the rate of decline of FEV1 in COPD (4).
Many things may have contributed to the equivocal findings
of TORCH, not the least of which being the statistical approach used
in the study. TORCH was a landmark study in COPD with more
than 6,000 participants potentially followed for 3 years. Inclusion
was based on having a prebronchodilator FEV1 of ,60% predicted
with no requirement for a history of previous exacerbations, which
may not have identified a population at a sufficiently high risk of
dying. TORCH was one of the last large trials to use short-acting
bronchodilators as its comparator arm, which probably contributed
to the differential patient withdrawal (5). However, given the
disappointment and expense of conducting the TORCH study, it is
unsurprising that funders have been reluctant to revisit this topic.
The last 2 years have seen things change. The development of
single inhaler treatment with LABA1 long-acting antimuscarinic
(LAMA) drugs, which is now recommended for first line use in
COPD (6), led to large trials to determine whether adding an ICS to
this regime further reduced the exacerbation risk. These studies
recruited patients with a significant exacerbation history who,
coincidentally, were at higher risk of dying. Two studies, IMPACT
(Informing the Pathway of COPD Treatment) and ETHOS
(Efficacy and Safety of Triple Therapy in Obstructive Lung
Disease), have shown that triple therapy was more effective
than dual bronchodilators in preventing exacerbation and
hospitalization and that mortality, which was prospectively defined
as a secondary outcome, was lowest in the triple-treatment arms
(7, 8). More detailed analysis of the mortality data from IMPACT
has already been presented (9), and we now have new data
from Martinez and colleagues (pp. 553–564), the ETHOS
trialists, published in this issue of the Journal (10).
The ETHOS investigators recruited 8,509 patients with
COPD with a history of either two moderate exacerbations or
one severe exacerbation in the previous year if their FEV1 was
.50% predicted or at least one of either type of exacerbation if
the FEV1 was below this threshold. Patients were randomized to
receive a LAMA–LABA combination (glycopyrrolate/formoterol
fumarate [GFF] 18/9.6 mg) or an ICS–LABA (budesonide/
formoterol fumarate [BFF] 320/9.6 mg) or one of two doses of
an ICS–LAMA–LABA (budesonide/glycopyrrolate/formoterol
fumarate [BGF] 320/18/9.6 mg [320 BGF] or 160/18/9 mg). All
inhalers were given twice daily from a metered-dose inhaler for
1 year. In the paper by Martinez and colleagues, the vital status
of 387 patients not included in the original report was obtained,
allowing an intention-to-treat analysis on 99.6% of the study
population (10). Altogether, 170 deaths occurred in the year after
randomization, predominantly from cardiovascular and respiratory
causes. There was a 45% reduction in the risk of death among those
receiving 320 BGF compared with GFF, the additional cases making
little difference to the original estimate. The lower-dose regime of
BGF was numerically, but not significantly, different from GFF and
was no different from the ICS–LABA combination of BFF. These
data complement those of the earlier IMPACT analysis, in which
the once-daily combination of the more potent ICS fluticasone
furoate and the LABA vilanterol was associated with fewer deaths
irrespective of whether it was given with a LAMA (8). ETHOS used a
Cox proportional hazard model adjusted for lung function and age,
variables that were not used in the secondary Cox analysis in
TORCH, which still showed a nominally significant difference, with
a 19% reduction in risk (1).The ETHOS data suggest that a dose
response of effectiveness may exist for mortality in a way not seen
when exacerbations are the endpoint, with the number needed to
treat for a mortality gain with 320 BFF being 80 patients per year.
The effect of stopping prior therapy on the risk of subsequently
exacerbating have been extensively debated in relation to IMPACT
(11, 12), and similar concerns would apply to the ETHOS data. The
authors provide a robust defense of the validity of their findings for
mortality by first using a novel tipping-point analysis to model how
many deaths would be needed among the 30 patients lost to follow-
up to make the difference between treatments no longer significant.
Even if 8 of the 10 missing patients who received BGF died the
day after their last contact, that treatment would still decrease
mortality significantly. A further analysis based on excluding deaths
in the first 90 days of study, which might have been precipitated
by stopping treatment, did not change the primary findings.
Unsurprisingly, patients who were receiving more therapy, including
ICS, at randomization gained more benefit in the study from triple
therapy, in keeping with other observations that patients receiving
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ICS treatment are sicker (13). Similarly, those with a history of more
exacerbations showed a larger reduction in mortality with 320 BGF.
It is becoming clearer that the effect of either starting or stopping
ICS on exacerbation risk is influenced by the blood eosinophil count
(14, 15). In ETHOS, this appears to be true for mortality as well, with
patients with a higher eosinophil count being at greater risk of dying
when receiving GFF compared with 320 BGF. Further analysis of
this potentially important observation is needed.
Several important lessons come from these positive studies of ICS
andCOPDmortality. First, large studies allow formore complex analyses
than small ones, but to properly test their primary hypothesis, trialists
need to focus on patient groups at the greatest risk of experiencing the
events under study. Treatment that reducesmortality will only be seen to
work in patients who are at risk of dying. Second, neither the drug, the
delivery system, nor the dosage regime is crucial to preventing death with
ICS–LAMA–LABA treatment, but the dose of the corticosteroid chosen
may be. Finally, mortality is not different from other endpoints in
COPD studies, and a therapy that decreases exacerbations is likely to
reduce mortality if sufficient numbers of the right kind of patient are
studied. So, belatedly, the flame lit by TORCH is burning brightly again
and does offer hope to all those who have COPD after all. n
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Learning from the First Wave of the Pandemic in England, Wales, and
Northern Ireland
The year 2020 has been one like no other for intensive care medicine
owing to the coronavirus disease (COVID-19) pandemic. Many
countries experienced unprecedented demand on critical care
resources during the first half of the year, with some respite over
the summer, only to see demand rise again toward the end of
the year (1).
In this issue of the Journal, Doidge and colleagues (pp. 565–
574) describe how the characteristics and outcomes of patients with
COVID-19 admitted to ICUs in England, Wales, and Northern
Ireland changed over the first wave of the pandemic (2). This large
study from the well-established United Kingdom registry group
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